# GLI2

## Overview
GLI2 is a gene that encodes the GLI family zinc finger 2 protein, a transcription factor integral to the Hedgehog signaling pathway. This protein is characterized by its zinc finger DNA-binding domain, which enables it to regulate gene expression by acting as both a transcriptional activator and repressor. The GLI2 protein plays a pivotal role in embryonic development, particularly in processes such as cell type specification, pattern formation, and cell proliferation. It is essential for the proper functioning of the Sonic Hedgehog signaling pathway, influencing the development of structures like the neural tube and ventral forebrain. Mutations in the GLI2 gene are associated with various developmental disorders, including holoprosencephaly and Culler-Jones syndrome, and have been implicated in oncogenesis, highlighting its clinical significance (McClearyWheeler2014From; Hui2011Gli; Bear2014Pathogenic).

## Structure
The human GLI2 protein is a transcription factor involved in the Hedgehog signaling pathway. It contains a zinc finger DNA-binding domain, which is central to its function as a transcriptional regulator (Roessler2005A). The protein also includes a carboxy-terminal activation domain and an amino-terminal repressor domain, which are crucial for its dual role as both an activator and repressor of transcription (Sadam2016GLI2; Roessler2005A). The amino-terminal domain, which extends the protein by 328 amino acids, functions as a transcriptional repressor and is necessary for the dominant-negative activity of certain GLI2 mutants (Roessler2005A).

GLI2 undergoes post-translational modifications, such as phosphorylation by protein kinase A, casein kinase 1, and glycogen synthase kinase 3, which regulate its degradation through the ubiquitin-proteasome pathway (Pan2006Sonic). Alternative splicing and transcriptional regulation lead to the production of various GLI2 isoforms, including GLI2ΔN and GLI2ΔC, which have distinct functional roles in different cellular contexts (Sadam2016GLI2). These isoforms separate the activator and repressor functions of GLI2 into distinct proteins, contributing to its complex regulatory mechanisms (Sadam2016GLI2).

## Function
GLI2 is a transcription factor that plays a crucial role in the Hedgehog (Hh) signaling pathway, acting primarily as a transcriptional activator in healthy human cells. It is essential for embryogenesis and mediates the transcriptional output of Sonic Hedgehog (Shh) signaling, which is vital for proper development (Hui2011Gli). GLI2 is involved in the regulation of gene expression by binding to DNA, influencing processes such as cell type specification, pattern formation, and regulation of cell proliferation (Ikram2004GLI2). 

In the context of the neural tube, GLI2 is the principal activator of Shh signaling, necessary for generating the highest Shh signaling response and specifying Shh+/Foxa2+ floor plate cells (Hui2011Gli). It also plays a role in the development of the ventral forebrain and the division of the primordial eye field and brain into two halves (Roessler2003Lossoffunction). 

GLI2 is expressed in normal human epidermis and the outer root sheath of hair follicles, where it regulates epidermal proliferation and induces GLI1 expression by binding to its promoter, suggesting a positive feedback loop between GLI1 and GLI2 (Ikram2004GLI2).

## Clinical Significance
Mutations and alterations in the GLI2 gene are associated with a variety of developmental disorders and cancers. GLI2 mutations can lead to congenital malformations such as holoprosencephaly (HPE), characterized by incomplete forebrain separation, and are often accompanied by pituitary anomalies and postaxial polydactyly (Arnhold2015Role; Bear2014Pathogenic). These mutations are also linked to hypopituitarism, which can manifest as isolated growth hormone deficiency or combined pituitary hormone deficiency, often with an ectopic posterior pituitary lobe (Arnhold2015Role). The inheritance pattern is typically autosomal dominant with incomplete penetrance (Arnhold2015Role).

In cancer, GLI2 acts as an oncogene, promoting cell proliferation and metastasis. Overexpression of GLI2 has been identified in several tumor types, including basal cell carcinoma, prostate cancer, and melanoma (McClearyWheeler2014From). GLI2 upregulates genes that promote cell cycle progression and downregulates cell cycle inhibitors, contributing to tumorigenesis (McClearyWheeler2014From). Inhibition of GLI2 can lead to increased expression of cell cycle inhibitors like p16, resulting in cell senescence (McClearyWheeler2014From). 

GLI2 mutations are also implicated in Culler-Jones syndrome, which presents with postaxial polydactyly, multiple pituitary hormone deficiencies, and dysmorphic facial features (Zhang2023Case).

## Interactions
GLI2, a transcription factor in the Hedgehog signaling pathway, engages in several critical interactions with proteins and nucleic acids. It interacts with the protein βTrCP in a phosphorylation-dependent manner, where phosphorylated GLI2 binds to βTrCP, facilitating its ubiquitination and degradation by the proteasome. This interaction is crucial for regulating GLI2 stability and is mediated by specific phosphorylation sites on GLI2 targeted by protein kinase A (PKA), casein kinase 1 (CK1), and glycogen synthase kinase 3 (GSK3) (Pan2006Sonic).

GLI2 also functions as a transcriptional activator by interacting with various protein complexes. It binds to the Taf9/TafII-31 subunit of the TFIID complex, enhancing its transcriptional activation potency. The mediator complex, including subunits like Med1, Med12, Med14, Med23, and CDK8, modulates GLI2's transcriptional activity. The Paf1 complex, through Parafibromin/Hprt2, binds to GLI2's N-terminal region, contributing to its activation role. Histone acetylation by coactivators such as CBP and Ep300 further supports GLI2-mediated transcription (Niewiadomski2019Gli).

In osteoblasts, GLI2 directly interacts with the BMP-2 promoter through specific Gli binding sites, facilitating BMP-2 expression in response to hedgehog signaling. This interaction is confirmed by chromatin immunoprecipitation and electrophoretic mobility shift assays (Zhao2006The).


## References


[1. (Pan2006Sonic) Yong Pan, Chunyang Brian Bai, Alexandra L. Joyner, and Baolin Wang. Sonic hedgehog signaling regulates gli2 transcriptional activity by suppressing its processing and degradation. Molecular and Cellular Biology, 26(9):3365–3377, May 2006. URL: http://dx.doi.org/10.1128/mcb.26.9.3365-3377.2006, doi:10.1128/mcb.26.9.3365-3377.2006. This article has 419 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.26.9.3365-3377.2006)

[2. (Roessler2003Lossoffunction) Erich Roessler, Yang-Zhu Du, Jose L. Mullor, Esther Casas, William P. Allen, Gabriele Gillessen-Kaesbach, Elizabeth R. Roeder, Jeffrey E. Ming, Ariel Ruiz i Altaba, and Maximilian Muenke. Loss-of-function mutations in the human gli2 gene are associated with pituitary anomalies and holoprosencephaly-like features. Proceedings of the National Academy of Sciences, 100(23):13424–13429, October 2003. URL: http://dx.doi.org/10.1073/pnas.2235734100, doi:10.1073/pnas.2235734100. This article has 270 citations.](https://doi.org/10.1073/pnas.2235734100)

[3. (McClearyWheeler2014From) Angela L. McCleary-Wheeler. From normal development to disease: the biochemistry and regulation of gli2. Medical Epigenetics, 2(1):1–19, February 2014. URL: http://dx.doi.org/10.1159/000358364, doi:10.1159/000358364. This article has 8 citations.](https://doi.org/10.1159/000358364)

[4. (Hui2011Gli) Chi-chung Hui and Stephane Angers. Gli proteins in development and disease. Annual Review of Cell and Developmental Biology, 27(1):513–537, November 2011. URL: http://dx.doi.org/10.1146/annurev-cellbio-092910-154048, doi:10.1146/annurev-cellbio-092910-154048. This article has 573 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1146/annurev-cellbio-092910-154048)

[5. (Arnhold2015Role) Ivo J P Arnhold, Marcela M França, Luciani R Carvalho, Berenice B Mendonca, and Alexander A L Jorge. Role of gli2 in hypopituitarism phenotype. Journal of Molecular Endocrinology, 54(3):R141–R150, June 2015. URL: http://dx.doi.org/10.1530/jme-15-0009, doi:10.1530/jme-15-0009. This article has 47 citations and is from a peer-reviewed journal.](https://doi.org/10.1530/jme-15-0009)

[6. (Zhang2023Case) Yiwen Zhang, Bingzi Dong, Yu Xue, Yunyang Wang, Jing Yan, and Lili Xu. Case report: a case of culler-jones syndrome caused by a novel mutation of gli2 gene and literature review. Frontiers in Endocrinology, March 2023. URL: http://dx.doi.org/10.3389/fendo.2023.1133492, doi:10.3389/fendo.2023.1133492. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2023.1133492)

[7. (Roessler2005A) Erich Roessler, Alexandre N. Ermilov, Dorothy Katherine Grange, Aiqin Wang, Marina Grachtchouk, Andrzej A. Dlugosz, and Maximilian Muenke. A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human gli2. Human Molecular Genetics, 14(15):2181–2188, June 2005. URL: http://dx.doi.org/10.1093/hmg/ddi222, doi:10.1093/hmg/ddi222. This article has 142 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddi222)

[8. (Sadam2016GLI2) Helle Sadam, Urmas Liivas, Anna Kazantseva, Priit Pruunsild, Jekaterina Kazantseva, Tõnis Timmusk, Toomas Neuman, and Kaia Palm. Gli2 cell-specific activity is controlled at the level of transcription and rna processing: consequences to cancer metastasis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1862(1):46–55, January 2016. URL: http://dx.doi.org/10.1016/j.bbadis.2015.10.008, doi:10.1016/j.bbadis.2015.10.008. This article has 10 citations.](https://doi.org/10.1016/j.bbadis.2015.10.008)

[9. (Ikram2004GLI2) Mohammed S. Ikram, Graham W. Neill, Gerhard Regl, Thomas Eichberger, Anna-Maria Frischauf, Fritz Aberger, Anthony Quinn, and Mike Philpott. Gli2 is expressed in normal human epidermis and bcc and induces gli1 expression by binding to its promoter. Journal of Investigative Dermatology, 122(6):1503–1509, June 2004. URL: http://dx.doi.org/10.1111/J.0022-202X.2004.22612.X, doi:10.1111/j.0022-202x.2004.22612.x. This article has 208 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1111/J.0022-202X.2004.22612.X)

[10. (Niewiadomski2019Gli) Paweł Niewiadomski, Sylwia M. Niedziółka, Łukasz Markiewicz, Tomasz Uśpieński, Brygida Baran, and Katarzyna Chojnowska. Gli proteins: regulation in development and cancer. Cells, 8(2):147, February 2019. URL: http://dx.doi.org/10.3390/cells8020147, doi:10.3390/cells8020147. This article has 125 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells8020147)

[11. (Zhao2006The) Ming Zhao, Mei Qiao, Stephen E. Harris, Di Chen, Babatunde O. Oyajobi, and Gregory R. Mundy. The zinc finger transcription factor gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. Molecular and Cellular Biology, 26(16):6197–6208, August 2006. URL: http://dx.doi.org/10.1128/mcb.02214-05, doi:10.1128/mcb.02214-05. This article has 108 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.02214-05)

[12. (Bear2014Pathogenic) Kelly A Bear, Benjamin D Solomon, Sonir Antonini, Ivo J P Arnhold, Marcela M França, Erica H Gerkes, Dorothy K Grange, Donald W Hadley, Jarmo Jääskeläinen, Sabrina S Paulo, Patrick Rump, Constantine A Stratakis, Elizabeth M Thompson, Mary Willis, Thomas L Winder, Alexander A L Jorge, Erich Roessler, and Maximilian Muenke. Pathogenic mutations ingli2cause a specific phenotype that is distinct from holoprosencephaly. Journal of Medical Genetics, 51(6):413–418, April 2014. URL: http://dx.doi.org/10.1136/jmedgenet-2013-102249, doi:10.1136/jmedgenet-2013-102249. This article has 50 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmedgenet-2013-102249)